As a result, tirzepatide prescriptions lead to higher weight loss totals, on average, more than semaglutide
(2024) 187:117790.e18
New Yorks law sets the precedent
Lancet 392(10148):637649 Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A et al (2021) Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial
Research on MOTS-c in ovariectomized mice (a model for postmenopausal metabolic dysfunction) showed reduced fat accumulation in white adipose tissue, increased brown fat activation, and improved insulin sensitivity after just 5 weeks of treatment
[see Warnings and Precautions (5.4) ]